Literature DB >> 25893037

Peptidic inhibitors for in vitro pentamer formation of human papillomavirus capsid protein l1.

Ding-Yi Fu1, Shi Jin1, Dong-Dong Zheng1, Xiao Zha2, Yuqing Wu1.   

Abstract

A new 14 peptide, originating essentially from the helix 5 of HPV 16L1, illustrates an IC50 of 19.38 nM for the inhibition of HPV 16 L1 pentamer formation, which is highly efficient for targeting a specific protein segment. In addition, mechanism studies reveal that the length, sequence, and the folding of the peptide are critical factors for its inhibition. Particularly, the peptide shows similar inhibition against the pentamer formation of HPV 58L1, although it is designed specially for HPV 16 L1. This study opens a way for the development of high-efficiency, broad-spectrum inhibitors as a new class of anti-HPV agents, which could be extended to the treatment of other virus types.

Entities:  

Keywords:  Peptide; human papillomavirus; inhibitor; pentamer formation

Year:  2015        PMID: 25893037      PMCID: PMC4394338          DOI: 10.1021/ml500392y

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  30 in total

1.  The potential of human papillomavirus vaccines.

Authors:  Robert Steinbrook
Journal:  N Engl J Med       Date:  2006-03-16       Impact factor: 91.245

Review 2.  The papillomavirus major capsid protein L1.

Authors:  Christopher B Buck; Patricia M Day; Benes L Trus
Journal:  Virology       Date:  2013-06-22       Impact factor: 3.616

3.  Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1.

Authors:  X S Chen; G Casini; S C Harrison; R L Garcea
Journal:  J Mol Biol       Date:  2001-03-16       Impact factor: 5.469

Review 4.  Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.

Authors:  T C Pomfret; J M Gagnon; A T Gilchrist
Journal:  J Clin Pharm Ther       Date:  2011-02       Impact factor: 2.512

5.  HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.

Authors:  Troy J Kemp; Allan Hildesheim; Mahboobeh Safaeian; Joseph G Dauner; Yuanji Pan; Carolina Porras; John T Schiller; Douglas R Lowy; Rolando Herrero; Ligia A Pinto
Journal:  Vaccine       Date:  2011-01-15       Impact factor: 3.641

Review 6.  Human papillomavirus vaccines: new tools for accelerating cervical cancer prevention in developing countries.

Authors:  Silvana Luciani; Barbara Jauregui; Clemence Kieny; Jon Kim Andrus
Journal:  Immunotherapy       Date:  2009-09       Impact factor: 4.196

7.  Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.

Authors:  Patricia M Day; Carl C Baker; Douglas R Lowy; John T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

8.  The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding.

Authors:  Rhonda C Kines; Cynthia D Thompson; Douglas R Lowy; John T Schiller; Patricia M Day
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-17       Impact factor: 11.205

9.  The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.

Authors:  Marc Brisson; Nicolas Van de Velde; Philippe De Wals; Marie-Claude Boily
Journal:  Vaccine       Date:  2007-05-22       Impact factor: 3.641

10.  Structure-based engineering of papillomavirus major capsid l1: controlling particle assembly.

Authors:  Brooke Bishop; Jhimli Dasgupta; Xiaojiang S Chen
Journal:  Virol J       Date:  2007-01-08       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.